A Post-market, Observational Registry With the easyEndoTM Universal Linear Cutting Stapler in Laparoscopic Bariatric Surgery (STAP-Delta)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Bart Smet, Dr.
- Phone Number: +32 (0)51 23 71 09
- Email: bart.smet@azdelta.be
Study Locations
-
-
-
Roeselare, Belgium
- AZ Delta vzw
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient ≥ 18 years of age at registry entry.
- Patient and investigator signed and dated the informed consent form prior to the index-procedure.
- Patient has a BMI ≥ 35 kg/m2, with one or more related co-morbidities.
- Patient has a BMI ≥ 40 kg/m2.
- Patient is eligible for laparoscopic bariatric surgery.
Exclusion Criteria:
- Patient is unable / unwilling to provide informed consent.
- Patient has a history of bariatric surgery.
- Patient is unable to comply with the registry protocol or proposed follow-up visits.
- Patient has a contra-indication for laparoscopic bariatric surgery.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Obese patients eligible for laparoscopic bariatric surgery
|
Investigational device: easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical).
Device for creation of anastomoses during laparoscopic bariatric surgery, manufactured by Ezisurg Medical.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: At index procedure
|
Conversion rate, number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
At index procedure
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: At discharge, up to 1 week
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
At discharge, up to 1 week
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: Follow-up 1: 3 weeks after the procedure
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
Follow-up 1: 3 weeks after the procedure
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: Follow-up 2: 8 weeks after the procedure
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
Follow-up 2: 8 weeks after the procedure
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: Follow-up 3: 6 months after the procedure
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
Follow-up 3: 6 months after the procedure
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: Follow-up 4: 12 months after the procedure
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
Follow-up 4: 12 months after the procedure
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: Follow-up 5: 18 months after the procedure
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
Follow-up 5: 18 months after the procedure
|
|
To evaluate the safety of the easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical) in laparoscopic bariatric surgery.
Time Frame: Follow-up 6: 24 months after the procedure
|
Number of re-interventions and number of participants with (serious) adverse events ≥ grade II Clavien-Dindo.
|
Follow-up 6: 24 months after the procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Device performance
Time Frame: At index procedure
|
Number of procedures with technical success defined as bariatric surgery as intended, without technical difficulties and without conversion to open laparotomy.
|
At index procedure
|
|
Device performance
Time Frame: At index procedure
|
Assessment of device performance (e.g.
sharpness of the blade, staple-line formation, etc.).
|
At index procedure
|
|
Clinical efficacy
Time Frame: Follow-up 1: 3 weeks after the procedure
|
Weight loss
|
Follow-up 1: 3 weeks after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 2: 8 weeks after the procedure
|
Weight loss
|
Follow-up 2: 8 weeks after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 3: 6 months after the procedure
|
Weight loss
|
Follow-up 3: 6 months after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 4: 12 months after the procedure
|
Weight loss
|
Follow-up 4: 12 months after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 5: 18 months after the procedure
|
Weight loss
|
Follow-up 5: 18 months after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 6: 24 months after the procedure
|
Weight loss
|
Follow-up 6: 24 months after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 4: 12 months after the procedure
|
Comorbidity
|
Follow-up 4: 12 months after the procedure
|
|
Clinical efficacy
Time Frame: Follow-up 6: 24 months after the procedure
|
Comorbidity
|
Follow-up 6: 24 months after the procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bart Smet, Dr., AZ Delta vzw
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- DM-Delta-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT03219658Completed
-
NCT03899311Completed
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
Clinical Trials on easyEndoTM Universal Linear Cutting Stapler and reloads (Ezisurg Medical)
-
NCT03968757CompletedObesity | Roux-en-Y Gastric Bypass
-
NCT04808206Active, not recruitingObesity | Roux-en-Y Gastric Bypass | Gastrostomy | Nissen Sleeve
-
NCT04543526Withdrawn
-
NCT07345013CompletedThoracic Surgery
-
NCT06555276Not yet recruiting
-
NCT03306966Withdrawn